Relationship of Prostate-Specific Antigen Velocity to Histologic Findings in a Prostate Cancer Screening Program

Urology

Volumn 71, Issue 6, 2008, Pages 1016-1019

  Eggener, Scott E ^a   Yossepowitch, Ofer ^a   Roehl, Kimberly A ^b   Loeb, Stacy ^c   Yu, Xiaoying ^d   Catalona, William J ^d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS;

BIOPSY; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 44649157173     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.12.008     Document Type: Article

References (17)

1. Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267 (1992) 2215-2220
2. Etzioni R.D., Howlader N., Shaw P.A., et al. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol 174 (2005) 877-881
3. Inoue L.Y., Etzioni R., Slate E.H., et al. Combining longitudinal studies of PSA. Biostatistics 5 (2004) 483-500
4. Smith D.S., and Catalona W.J. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 152 (1994) 1163-1167
5. Whittemore A.S., Lele C., Friedman G.D., et al. Prostate-specific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst 87 (1995) 354-360
6. Berger A.P., Deibl M., Steiner H., et al. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. Prostate 64 (2005) 240-245
7. Eggener S.E., Roehl K.A., and Catalona W.J. Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy. J Urol 174 (2005) 500-504
8. Schroder F.H., Roobol M.J., van der Kwast T.H., et al. Does PSA velocity predict prostate cancer in pre-screened populations?. Eur Urol 49 (2006) 460-465 discussion 5
9. Thompson I.M., Ankerst D.P., Chi C., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529-534
10. Catalona W.J., Smith D.S., and Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: enhancement of specificity with free PSA measurements. JAMA 277 (1997) 1452-1455
11. Yu X., Loeb S., Roehl K.A., et al. The association between total prostate specific antigen concentration and prostate specific antigen velocity. J Urol 177 (2007) 1298-1302 discussion 301-302
12. Harrell F. Regression Modeling Strategies (2001), Springer-Verlag, New York
13. Begg C.B., and Greenes R.A. Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics 39 (1983) 207-215
14. Hunink M.G., Richardson D.K., Doubilet P.M., et al. Testing for fetal pulmonary maturity: ROC analysis involving covariates, verification bias, and combination testing. Med Decis Making 10 (1990) 201-211
15. Carter H.B. PSA variability versus velocity. Urology 49 (1997) 305
16. Eastham J.A., Riedel E., Scardino P.T., et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 289 (2003) 2695-2700
17. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350 (2004) 2239-2246